Lilly eases investors' jitters with strong 2017 forecast

(Reuters) - Eli Lilly and Co, in a move that appeared to ease investor concerns after the failure of its high-profile Alzheimer's drug, on Thursday provided a 2017 forecast above Wall Street estimates and expressed confidence in recently launched products and those in development.